Zanubrutinib versus bendamustine and rituximab in untreated patients with CLL/SLL Zanubrutinib versus bendamustine and rituximab in untreated patients with CLL/SLL February 2025 Clinical trials Read more
2024 October EHA 2024 Superior tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgk... Read more
2024 October EHA 2024 Mitapivat safe and effective in non-transfusion-dependent thalassaemia Read more
2024 October EHA 2024 ATRA-ATO regimen improves event-free survival in patients with newly diagnosed high-risk acute... Read more
2024 October EHA 2024 Acalabrutinib plus chemoimmunotherapy reduces the risk of disease progression or death in elde... Read more
2024 October EHA 2024 Isa-VRd as a new standard of care for patients with transplant-ineligible newly-diagnosed mult... Read more
2024 October EHA 2024 Frontline blinatumomab active in Down Syndrome B-cell acute lymphoblastic leukaemia Read more